0001562555-25-000001.txt : 20250130
0001562555-25-000001.hdr.sgml : 20250130
20250129194143
ACCESSION NUMBER: 0001562555-25-000001
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
ITEM INFORMATION: Investment Company Act Section 3(c)
ITEM INFORMATION: Section 3(c)(1)
FILED AS OF DATE: 20250130
DATE AS OF CHANGE: 20250129
EFFECTIVENESS DATE: 20250130
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ataraxa LP
CENTRAL INDEX KEY: 0002053057
ORGANIZATION NAME:
IRS NUMBER: 331389977
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-536778
FILM NUMBER: 25570722
BUSINESS ADDRESS:
STREET 1: 817 BROADWAY
STREET 2: 12TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10003
BUSINESS PHONE: 347-614-2682
MAIL ADDRESS:
STREET 1: 817 BROADWAY
STREET 2: 12TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10003
D
1
primary_doc.xml
X0708
D
LIVE
0002053057
Ataraxa LP
817 BROADWAY
12TH FLOOR
NEW YORK
NY
NEW YORK
10003
347-614-2682
DELAWARE
None
None
Limited Partnership
true
2024
n/a
Ataraxa GP LLC
817 Broadway
12th Floor
New York
NY
NEW YORK
10003
Executive Officer
General Partner of Issuer
n/a
Avenir Management Company, LLC
817 Broadway
12th Floor
New York
NY
NEW YORK
10003
Executive Officer
Investment Manager of Issuer
Andrew
Sugrue
817 Broadway
12th Floor
New York
NY
NEW YORK
10003
Promoter
Manager of Issuer's General Partner and Investment Manager
James
Reynolds IV
817 Broadway
12th Floor
New York
NY
NEW YORK
10003
Promoter
Manager of Issuer's General Partner and Investment Manager
Pooled Investment Fund
Hedge Fund
false
Decline to Disclose
- 06b
- 3C
- 3C.1
false
2025-01-15
true
true
false
10000
Indefinite
1035000
Indefinite
The reported amount sold and number of investors represent total contributions by all investors in the issue since inception. The current assets under management and current number of investors may be significantly different.
false
8
0
0
0
The issuer's General Partner, Investment Manager (or an affiliate) is entitled to a management fee in an amount based on a percentage of assets and under management.
false
Ataraxa LP
Christopher DeLuca
Christopher DeLuca
Authorized Person
2025-01-29